|
|
|
| Effect of transcatheter arterial chemoembolization combined with Sorafenib in the treatment of advanced hepatocellular carcinoma |
| WANG Chunyan1 WU Bin1 LAN Chuan1 DENG Dawei1 ZHANG Guangnian1 LENG Zhengwei2 LI Jianshui1 |
1.Department of Hepatobiliary Surgery, the Affiliated Hospital of North Sichuan Medical College, Sichuan Province, Nanchong 637000, China;
2.Department of General Surgery, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Hubei Province, Wuhan 430022, China |
|
|
|
Abstract Objective To assess the therapeutic effect of transcatheter arterial chemoembolization (TACE) combined with Sorafenib in the treatment of advanced hepatocellular carcinoma. Methods The clinical data of 88 patients with advanced hepatocellular carcinoma hospitalized in the Affiliated Hospital of North Sichuan Medical College from January 2012 to January 2016 was analyzed retrospectively. The patients were divided into TACE group and TACE + Sorafenib group (combined group), with 44 cases in each group. The disease control rate, incidence of adverse reactions, half-year survival rate, one-year survival rate of the two groups were analyzed. Results The disease control rate of combined group was 54.5%, which was higher than that of TACE group (29.5%), the difference was statistically significant (P ＜ 0.05); the incidence of adverse reactions in combined group was 81.8%, which of TACE group was 84.1%, there was no significant difference between the two groups (P ＞ 0.05). The half-year survival rate and one-year survival rate in combined group was 59.1%, 47.7% respectively, which was significantly higher than those of TACE group (36.4%, 25.0%), the differences were all statistically significant (all P ＜ 0.05). Conclusion TACE combined with Sofafenib in the treatment of advanced hepatocellular carcinoma is feasible, the therapeutic effect is good, the long-term lifetime is prolonged, the tolerance is well, which is worthy of clinical promotion.
|
|
|
|
|
|
[1] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[2] Llovet JM，Zucman-Rossi J，Pikarsky E，et al. Hepatocellular carcinoma [J]. Nat Rev Dis Primers，2016，2：16018.
[3] Raoul JL，Sangro B，Forner A，et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma：available evidence and expert opinion on the use of transarterial chemoembolization [J]. Cancer Treat Rev，2011，37（3）：212-220.
[4] 张潇颖，林子琦，薛平，等.重症急性胰腺炎患者初期合并不同水平高血糖的临床研究[J].四川大学学报：医学版，2013，44（6）：974-977，986.
[5] Zhang B，Liu K，Zhang J，et al. Glutamine synthetase predicts adjuvant TACE response in hepatocellular carcinoma [J]. Int J Clin Exp Med，2015，8（11）：20722-20731.
[6] Yao X，Yan D，Zeng H，et al. Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma [J]. J Surg Oncol，2016，113（6）：672-677.
[7] 王卫东，黄巧胜，倪嘉延，等.TACE与索拉菲尼联合治疗中晚期肝癌临床研究的Meta分析[J].临床放射学杂志，2015，34（11）：1816-1821.
[8] 丁文金，李飞平，龚光文，等.TACE联合索拉菲尼与TACE治疗巴塞罗那B期肝癌的临床对比研究[J].肿瘤药学，2015，5（3）：230-234.
[9] 杨曼.索拉菲尼联合肝动脉化疗栓塞术治疗肝癌的疗效和预后分析研究[D].西安：第四军医大学，2014.
[10] 陈世晞，陈骏，席玮，等.TACE联合分子靶向药索拉菲尼治疗晚期肝癌远期疗效观察[J].介入放射学杂志，2011， 20（12）：958-960.
[11] Chan SL，Wong AM，Lee K，et al. Personalized therapy for hepatocellular carcinoma：Where are we now? [J]. Cancer Treat Rev，2016，45：77-86.
[12] Petrelli F，Coinu A，Borgonovo K，et al. Oxaliplatin-based chemotherapy：a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis [J]. Clin Oncol（R Coll Radiol），2014，26（8）：488-496.
[13] 叶新平，尚丽明，苏智雄，等.TACE联合索拉非尼治疗不能再手术的复发性肝细胞癌的临床分析[J].实用医学杂志，2014，30（22）：3660-3662.
[14] 梁恒毅.索拉非尼联合经皮肝动脉化疗栓塞及射频消融治疗大于5cm中晚期肝细胞癌程序化方案的探索性研究[D].广州：南方医科大学，2013.
[15] 李明非，杨远，曾勇，等.TACE与索拉非尼在晚期肝癌治疗中的疗效比较[J].西部医学，2015，27（9）：1299-1302.
[16] 陈彬，李德周.早期序贯RFA结合TACE治疗合并乙型肝炎肝硬化的大肝癌患者临床观察[J].中国现代医生，2016，54（16）：88-91，95.
[17] 付宁，李正平，罗道蕴，等.肝动脉化疗栓塞术中植入氟尿嘧啶、奥沙利铂、吡柔比星治疗中晚期原发性肝癌的临床研究[J].成都医学院学报，2015，10（6）：652-656.
[18] 鲍建勋，王号飞，黄云娟.人参皂苷Rg3联合奥沙利铂和索拉非尼对肝癌细胞凋亡的影响[J].中国生化药物杂志，2014，34（1）：41-42.
[19] 刘墨，王萍菊，樊喜文，等.海藻酸钠-TACE治疗肝癌早期肝功能损伤及并发症分析[J].中国医学创新，2016， 13（23）：46-48.
[20] 胡鸿涛，黎海亮，郭晨阳，等.索拉非尼联合三氧化二砷治疗原发性肝癌肺转移[C].全国临床肿瘤学大会暨2012年csco学术年会，2012. |
|
|
|
